ByteDance Sold 44% of Its AI Pharmaceuticals Business for $290 Million: A Good Deal or a Bold Bet?
Hello everyone, I'm your financial journalist. Today, we're talking about a news story that's causing a stir in both the tech and pharmaceutical industries: ByteDance's AI pharmaceutical division, Anew Labs, has completed a $290 million Series A financing round, with a post-financing valuation of $1.5 billion.
At first glance, it might seem like a typical case of a large company splitting off to go public. But if you break down the details of the deal, the list of investors involved, and the untested “trump card” in their hands, you realize that this is more than just a financial transaction—it's a significant move in ByteDance's strategy for the second half of the AI revolution.
To make this complex financial news easier to understand, I've broken it down into five key points in plain language.
---
1. What Exactly Did ByteDance Sell?
It didn't sell the entire company; it sold a portion of its interests.
When people hear “financing,” their first thought might be, “Does ByteDance need money?”
Not at all. ByteDance has plenty of cash on hand. By giving up 44% of its shares in exchange for $290 million and a $1.5 billion valuation, it's actually acquiring resources.
Let's look at who the investors are:
- Lead investors (HSG, IDG, Hillhouse): These are top-tier venture capitalists who are not only providing capital but also bringing valuable connections for future rounds of financing.
- Key non-financial investors (China Biopharmaceutical): In AI pharmaceuticals, the hardest part is not designing molecules in a lab but turning those molecules into actual drugs and selling them. China Biopharmaceutical has a complete clinical and commercialization framework. By bringing them in, ByteDance is essentially building a “highway” for Anew Labs to reach hospitals and pharmacies.
- Local state-owned funds (Shanghai Future Industry Fund): With its headquarters in Shanghai, the involvement of state-owned capital usually means access to government policies and subsidies.
In summary, ByteDance exchanged 44% of its shares for three things: cash, a valuation that confirms its worth of $1.5 billion, and access to industry and government resources. This “splitting up to attract capital while maintaining control” strategy is quite rare among large Chinese companies. Baidu went the route of having Baitu BioScience go public independently, while Tencent mainly relies on investments; ByteDance has chosen a third path.
---
2. Why a $1.5 Billion Valuation?
The valuation of $1.5 billion is 50% higher than what analysts were expecting ($1 billion). Anew Labs doesn't have any drugs in clinical trials or revenue from licensing yet. So, what’s behind this high valuation?
The answer lies in their technology, especially a molecule called AN-5162:
- Simple explanation: In the field of autoimmune diseases (such as psoriasis and rheumatoid arthritis), there’s a target called IL-17 that’s highly contested by pharmaceutical companies. Previous drugs (like Novartis’ secukinumab) only target one form of IL-17 (IL-17A).
- The Challenge: Another form, IL-17FF, has a unique structure that traditional small molecule drugs can’t target. Anew Labs claims their AI has designed a molecule that can inhibit all three forms of IL-17.
- The Value of the Technology: If this molecule proves effective, it would be a “full-spectrum” inhibitor, potentially disrupting the market. Investors are buying into the potential for a huge market monopoly in the future. Additionally, ByteDance’s previously open-sourced Protenix model has gained a good reputation in the academic community, adding to its technical value.
---
3. The Embarrassing Reality of Global AI Pharmaceuticals
Looking at the global landscape of AI pharmaceuticals, there’s a common issue: There’s plenty of money, but few actual drugs:
- Comparison: British company Isomorphic Labs just raised $2.1 billion, and American company Xaira raised $1.3 billion. Anew Labs’ $290 million might seem small, but it’s the largest among Chinese companies.
- The Crude Reality: As of mid-2026, out of the 180 new drug pipelines discovered by AI, only a few have entered phase III trials, and no AI-discovered drugs have been approved by the FDA.
- Why? AI is good at “chemistry” (designing molecular structures) and performs well in phase I trials (where safety is the main focus). However, phase II trials (which test efficacy) involve complex biological processes that algorithms can’t fully predict.
In essence, the valuations of all AI pharmaceutical companies are based on options—investors are betting on which company can overcome the biological challenges and turn these molecules into real drugs. Anew Labs’ $290 million is for these options, plus the potential value of IL-17FF.
---
4. The Challenges After Moving Outside the “Greenhouse”
ByteDance had a natural advantage in developing AI pharmaceuticals due to its massive computing power. Volcano Engine provided low-cost computing resources for Anew Labs. But now, as a separate company, new challenges arise:
- Data Bottleneck: The core of AI pharmaceuticals is data. Anew Labs outsources all its laboratory tests to CROs (contract research organizations).
- Risks: This could lead to issues with data quality and consistency.
- Comparison: Hangzhou Enhe Technology built its own “biological manufacturing facility” to record every experiment, using real data to train its models. This requires significant upfront investment but creates a strong foundation. Anew Labs’ approach is more streamlined, but its success depends on the cooperation of CROs.
- Talent Integration: ByteDance had multiple AI pharmaceutical projects (Anew Labs, SeedFold, Protenix, etc.). Now, with these merged into one company, internal competition could turn into collaboration. Will key scientists leave due to changes in benefits after the split?
In other words, Anew Labs, once a “privileged part” of ByteDance, now has to manage its own resources and data independently.
---
5. The Ultimate Test of Time
The final question is time:
- Key Milestone: Anew Labs plans to submit an IND (Investigational New Drug Application) for AN-5162 this quarter.
- A Long Journey: The average time from IND to market launch is several years, with a high clinical failure rate of over 70%.
- Patience Required: In 2027 and 2028, while other AI pharmaceutical companies are still losing money, Anew Labs will face a critical test:
1. Will the clinical data be as impressive as expected?
2. If it fails, will investors be willing to continue investing?
3. As the major shareholder, will ByteDance have the patience to support the long research and development process?
In summary, ByteDance’s move is a clever strategy for risk isolation and resource exchange. By separating its high-risk pharmaceutical business and bringing in experienced industry and government investors, it maintains control.
For the general public, what does this mean?
It means we might see more drugs designed by AI in hospitals in the coming years. But remember, AI is not a magic bullet; the real barriers lie in whether companies can successfully bring these molecules to clinical trials, collect real-world data, and endure the long wait.
Anew Labs’ $1.5 billion valuation is a costly entry ticket. The question is whether they can turn this investment into a life-saving drug.